On the other side, a purely genes-first model to explain all resistances to BTK inhibitors seems unlikely given the absence of target gene mutations in about 40% of patients and the extensive genomic investigations to which longitudinal CLL samples have been subjected [28]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.